進階搜尋


  查詢北醫館藏
系統識別號 U0007-2906201117584800
論文名稱(中文) 合成以吲哚為基礎之氮-羥基肉桂酸醯胺作為組蛋白去乙醯酶抑制劑
論文名稱(英文) Synthesis of Indole-Based N-Hydroxycinnamide as Inhibitors of Histone Deacetylase
校院名稱 臺北醫學大學
系所名稱(中) 生藥學研究所
系所名稱(英) Graduate Institute of Pharmacognosy
學年度 99
學期 2
出版年 100
研究生(中文) 李欣穎
研究生(英文) Hsin-Ying Li
學號 M303098015
學位類別 碩士
語文別 中文
口試日期 2011-06-16
論文頁數 151頁
口試委員 指導教授-黃偉展
委員-張崇毅
委員-忻凌偉
委員-林若凱
中文關鍵字 組蛋白去乙醯酶  抑制劑  癌症  合成      肉桂酸醯胺 
英文關鍵字 Histone Deacetylase Inhibitors  cancer  synthesi  indole cinnamide 
學科別分類
中文摘要 組蛋白去乙醯酶抑制劑為目前癌症標靶治療研究發展趨勢之一,其化學結構主要分為三部份:與鋅產生螯合之基團、疏水性鏈長以及疏水性辨認部位。本研究主要合成以吲哚為基礎之氮-羥基肉桂酸醯胺作為組蛋白去乙醯酶抑制劑。

以氮-羥基肉桂酸醯胺為模板,在不同之取代位向藉由不同碳鏈長度結合不同取代基之吲哚環,合成系列化合物6a-6i、6j-6k及10、15,以子宮頸癌細胞萃取之組蛋白去乙醯酶(HeLa nuclear HDAC)測試其活性,其中抑制活性最好之化合物6e、6l、6n,對於第一與第六型(HDAC-1, -6)組蛋白去乙醯酶之抑制活性與SAHA相當,而在第四及第八型(HDAC-4, -8)組蛋白去乙醯酶抑制活性中,均顯示較SAHA強之活性;而抑制活性最差之化合物6a、6b、6c,對於第一與第四型(HDAC-1, -4)組蛋白去乙醯酶之抑制效果亦均較SAHA差,而對於第八型(HDAC 8)組蛋白去乙醯酶之抑制活性則較SAHA強20倍以上,有潛力發展為選擇性第八型組蛋白去乙醯酶抑制劑。

在細胞抑制實驗中,化合物6n (GI50=0.13 μM)對於PC3細胞之抑制效果明顯強於SAHA (GI50=0.61 μM),證實以吲哚為基礎之氮-羥基肉桂酸醯胺之化合物6n具有發展為有效組蛋白去乙醯酶抑制劑抗癌藥物之潛力。
英文摘要 Histone deacetylase (HDAC) inhibitors have been validated as a potential agent for targeted cancer chemotherapy. The pharmacophore of reported HDAC inhibitor is composed of three moieties: a zinc-chelating group, a connection group consisting of linear or cyclic linker, and a hydrophobic cap for surface recognition. In this study, we have performed chemical synthesis and biological evaluation of indole-based N-Hydroxycinnamidesas series as histone deacetylase inhibitors.

Seventeen novel N-hydroxycinnamides capped with substituted-indole (compounds 6a~6i, 6j~6o and 10, 15) were synthesized in order to achieve structure optimization and screened for inhibitory activity against HeLa nuclear HDACs. Compound 6e, 6l, and 6n with potent nuclear HDACs inhibition showed not only SAHA-like activity towards HDAC-1,-6 inhibition, but also superior activity over SAHA against HDAC-4, -8 by about 6-, 10-fold difference, respectively. Interestingly, compounds 6a, 6b and 6c exhibited weak inhibitory activities against HeLa nuclear HDACs while showing superior inhibitory activities against HDAC 8 over other isoforms (HDAC1, -4, -6).

Further antiproliferative activity demonstrated that compound 6n showed strong cytotoxicity against PC3 (GI50=0.13 μM) comparable to that of SAHA (GI50=0.61 μM). This study suggested that indole-based N-hydroxycinnamide 6n, a potent histone deacetylase inhibitor, has the potential to develop as an anticancer agent.
論文目次 摘要……Ⅰ
Abstract……Ⅱ
表目錄……Ⅳ
流程圖目錄……Ⅴ
圖目錄……Ⅵ
附圖目錄……Ⅶ
Ⅰ.緒論與研究目的..1
Ⅱ.結果與討論….. 7
Ⅲ.結論……19
Ⅳ.實驗方法……20
1.儀器與材料……20
(a)一般儀器及方法……20
(b)試劑與溶劑來源……20
2.化學合成步驟及物理資料……22
3.生物活性分析……47
4.純度測定……48
Ⅴ.參考文獻……49
Ⅵ.附圖……53
參考文獻 1.Seddon BM, Workman P: The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol 2003, 76 Spec No 2:S128-138.
2.Sikora K, Advani S, Koroltchouk V, Magrath I, Levy L, Pinedo H, Schwartsmann G, Tattersall M, Yan S: Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 1999, 10(4):385-390.
3.Walkinshaw DR, Yang XJ: Histone deacetylase inhibitors as novel anticancer therapeutics. Current Oncology 2008, 15(5):237-243.
4.Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389(6648):251-260.
5.Lenfant F, Mann RK, Thomsen B, Ling X, Grunstein M: All four core histone N-termini contain sequences required for the repression of basal transcription in yeast. Embo Journal 1996, 15(15):3974-3985.
6.Santos-Rosa H, Caldas C: Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005, 41(16):2381-2402.
7.Cress WD, Seto E: Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000, 184(1):1-16.
8.Strahl BD, Allis CD: The language of covalent histone modifications. Nature 2000, 403(6765):41-45.
9.Gray SG, Ekstrom TJ: The human histone deacetylase family. Experimental Cell Research 2001, 262(2):75-83.
10.Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu XS et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. P Natl Acad Sci USA 2004, 101(2):540-545.
11.Vermeulen M, Walter W, Le Guezennec X, Kim J, Edayathumangalam RS, Lasonder E, Luger K, Roeder RG, Logie C, Berger SL et al: A feed-forward repression mechanism anchors the Sin3/histone deacetylase and N-CoR/SMRT corepressors on chromatin. Mol Cell Biol 2006, 26(14):5226-5236.
12.Mahlknecht U, Hoelzer D: Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000, 6(8):623-644.
13.Bryan EJ, Jokubaitis VJ, Chamberlain NL, Baxter SW, Dawson E, Choong DY, Campbell IG: Mutation analysis of EP300 in colon, breast and ovarian carcinomas. International Journal of Cancer 2002, 102(2):137-141.
14.Blander G, Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem 2004, 73:417-435.
15.Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T et al: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo Journal 2002, 21(11):2672-2681.
16.Dokmanovic M, Clarke C, Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5(10):981-989.
17.Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW: Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Molecular Cell 2008, 30(1):61-72.
18.Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O: Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2009, 18(11):1605-1617.
19.Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN: Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126(2):321-334.
20.Haberland M, Montgomery RL, Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10(1):32-42.
21.Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N et al: The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274.
22.Zhang Y, Gilquin B, Khochbin S, Matthias P: Two catalytic domains are required for protein deacetylation. Journal of Biological Chemistry 2006, 281(5):2401-2404.
23.Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K et al: The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunology 2009, 10(1):92-100.
24.Kazantsev AG, Thompson LM: Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Reviews Drug Discovery 2008, 7(10):854-868.
25.Noureen N, Rashid H, Kalsoom S: Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 2010, 66(4):625-633.
26.Miller TA, Witter DJ, Belvedere S: Histone deacetylase inhibitors. J Med Chem 2003, 46(24):5097-5116.
27.Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27(32):5459-5468.
28.Bertrand P: Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010, 45(6):2095-2116.
29.Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T: Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. Journal of Biological Chemistry 1993, 268(30):22429-22435.
30.Thaler F, Varasi M, Colombo A, Boggio R, Munari D, Regalia N, Rozio MG, Reali V, Resconi AE, Mai A et al: Synthesis and Biological Characterization of Amidopropenyl Hydroxamates as HDAC Inhibitors. Chemmedchem 2010, 5(8):1359-1372.
31.Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Experimental Cell Research 1998, 241(1):126-133.
32.Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999, 42(15):3001-3003.
33.Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F, Paquin I, Bernstein N, Bouchain G, Vaisburg A et al: Discovery of N-(2-aminophenyl)4-[4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 2008, 51(14):4072-4075.
34.Hogarth P, Lovrecic L, Krainc D: Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov Disord 2007, 22(13):1962-1964.
35.Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G et al: Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003, 307(2):720-728.
36.Marks PA: The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Inv Drug 2010, 19(9):1049-1066.
37.Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K et al: N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]-phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 2003, 46(21):4609-4624.
38.Bertrand P: Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010, 45(6):2095-2116.
39.Atadja P: Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. Cancer Lett 2009, 280(2):233-241.
40.Chen LQ, Petrelli R, Gao GY, Wilson DJ, McLean GT, Jayaram HN, Sham YY, Pankiewicz KW: Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorgan Med Chem 2010, 18(16):5950-5964.
41.Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett 2009, 277(1):8-21.
42.Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ: A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008, 22(5):1026-1034.
43.Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P et al: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. P Natl Acad Sci USA 2004, 101(42):15064-15069.
44.Witt O, Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM et al: Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. Clinical Cancer Research 2009, 15(1):91-99.


論文全文使用權限
  • 同意授權瀏覽/列印電子全文服務,於2016-08-18起公開。


  • 若您有任何疑問,請與我們聯絡!
    臺北醫學大學 圖書館 簡莉婷
    E-mail:etds@tmu.edu.tw
    Tel:(02) 2736-1661 ext.2519
    Fax:(02) 2737-5446